Chronic kidney disease (CKD) affects 10% of the global population. Medication dosing errors in people with impaired kidney ...
Renin–angiotensin system (RAS) inhibitors — including angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) — slow the progression of mild or moderate chronic kidney ...
In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results